7-chloro-1-cyclopropyl-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide

Catalog No. :
ACOGSK590
CAS No. :
-
Molecular Formula :
C26H20ClFN4O5
Molecular Weight :
522.92

IUPAC Name:7-chloro-1-cyclopropyl-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide

7-chloro-1-cyclopropyl-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$655.00Login to see priceIn stockInquiry
250mg95%$1309.00Login to see priceIn stockInquiry
1g95%$3920.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-chloro-1-cyclopropyl-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide
IUPAC Name7-chloro-1-cyclopropyl-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide
Molecular FormulaC26H20ClFN4O5
Molecular Weight522.92
SMILESO=C1CCC(N2CC3=C(NC(=O)C4=CN(C5CC5)C5=CC(Cl)=C(F)C=C5C4=O)C=CC=C3C2=O)C(=O)N1
InChI KeyTYCONIXVAREBGP-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACOGSK590 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  2. Plus
  3. ACZDNW785 route compound structure diagram
    ACZDNW78586393-33-1 In Stock
  4. Then
  5. ACOGSK590 route product structure diagram
    ACOGSK590- In Stock
Inquiry

2. ACOGSK590 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFVXI513 route compound structure diagram
    ACFVXI513191732-72-6 In Stock
  4. Then
  5. ACOGSK590 route product structure diagram
    ACOGSK590- In Stock
Inquiry

Comments (0)